{"id":67184,"date":"2026-06-03T13:53:37","date_gmt":"2026-06-03T05:53:37","guid":{"rendered":"https:\/\/flcube.com\/?p=67184"},"modified":"2026-06-03T13:53:38","modified_gmt":"2026-06-03T05:53:38","slug":"roches-oral-serd-giredestrant-receives-fda-priority-review-for-early-breast-cancer-adjuvant-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67184","title":{"rendered":"Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment"},"content":{"rendered":"\n

Roche Holding AG<\/strong> (SWX: ROP<\/a>, OTCMKTS: RHHBY<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has accepted its New Drug Application (NDA)<\/strong> for giredestrant<\/strong>\u2014an investigational oral selective oestrogen receptor degrader (SERD)<\/strong>\u2014under Priority Review<\/strong> for adjuvant treatment of early-stage ER-positive, HER2-negative breast cancer<\/strong>.<\/p>\n\n\n\n

The filing, supported by positive results from the Phase III lidERA Breast Cancer study<\/strong>, demonstrated a 30% reduction in invasive disease-free survival (iDFS) events<\/strong> compared to standard endocrine therapy, with an FDA decision expected by November 30, 2026<\/strong>.<\/p>\n\n\n\n

Regulatory Status & Timeline<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Regulatory Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Application Type<\/strong><\/td>New Drug Application (NDA)<\/td><\/tr>
Review Designation<\/strong><\/td>Priority Review<\/td><\/tr>
Target Indication<\/strong><\/td>Adjuvant treatment for ER+, HER2- stage I-III breast cancer<\/td><\/tr>
PDUFA Date<\/strong><\/td>November 30, 2026<\/td><\/tr>
Drug Class<\/strong><\/td>Oral selective oestrogen receptor degrader (SERD)<\/td><\/tr>
Development Stage<\/strong><\/td>Phase III completed, NDA under review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Phase III lidERA Trial Results<\/h2>\n\n\n\n
Endpoint<\/th>Giredestrant Arm<\/th>Standard-of-Care ET Arm<\/th>Hazard Ratio\/Comparison<\/th><\/tr><\/thead>
Invasive Disease-Free Survival (iDFS)<\/strong><\/td>30% risk reduction<\/td>Reference<\/td>Statistically significant<\/td><\/tr>
3-Year iDFS Rate<\/strong><\/td>92.4%<\/td>89.6%<\/td>+2.8 percentage points<\/td><\/tr>
Treatment Discontinuation Rate<\/strong><\/td>5.3%<\/td>8.2%<\/td>Better tolerability<\/td><\/tr>
Safety Profile<\/strong><\/td>Well tolerated<\/td>Standard ET profile<\/td>Favorable benefit-risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Clinical Significance<\/h2>\n\n\n\n